Visipaque approved in USA



Date: Mon, 22.Apr 1996 From: HafslundNycomed

Visipaque? approved in USA

Hafslund Nycomed (NYSE: HN) announced today that its third-generation X-ray contrast agent, Visipaque?, is now approved by the U.S. Food and Drug Administration (FDA) for marketing in the USA.

Visipaque?, unlike the other non-ionic X-ray contrast agents available in the market, is isotonic with human blood. This reduces discomfort for patients who are given injections of contrast agent into the bloodstream, which is the most common mode of use for such products.

Visipaque? is the only third-generation X-ray contast agent of this type in the world which is marketed for general use in a broad range of indications. Visipaque? has already been launched in 11 European countries and sales developments are positive.

Oslo, Norway
April 22, 1996

Contacts

  • Hafslund

Subscribe